Enanta Pharmaceuticals, Inc. (ENTA)

Market Cap	327.42M +164.5%
Revenue (ttm)	69.21M +7.4%
Net Income	-61.98M
EPS	-2.47
Shares Out	29.08M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	135,055
Open	11.68
Previous Close	11.73
Day's Range	11.25 - 11.68
52-Week Range	6.44 - 17.15
Beta	0.99
Analysts	Strong Buy
Price Target	20.14 (+78.86%)
Earnings Date	May 11, 2026

About ENTA

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company’s product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urtica...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 21, 2013
• Employees: 120
• Stock Exchange: NASDAQ
• Ticker Symbol: ENTA
• Website: https://www.enanta.com

Financial Performance

In fiscal year 2025, Enanta Pharmaceuticals's revenue was $65.32 million, a decrease of -3.42% compared to the previous year's $67.64 million. Losses were -$81.89 million, -29.43% less than in 2024.

Analyst Summary

According to 6 analysts, the average rating for ENTA stock is "Strong Buy." The 12-month stock price target is $20.14, which is an increase of 78.86% from the latest price.

Price Target

$20.14

(78.86% upside)

Analyst Consensus: Strong Buy